Australia’s biotechnology major Starpharma has received regulatory approvals to launch a newly developed condom gel that will help fight STIs

Singapore: Australia's biotechnology company, Starpharma has received a regulatory approval for the sale of its revolutionary new product in the country.

The company has developed a virus-fighting VivaGel, a range of revolutionary condoms, featuring a gel that attacks sexually transmitted viruses.

The company said that they developed the unique gel with the hope of reducing the growing prevalence of sexually transmitted infections (STIs).

In an official statement, the company explained that the VivaGel lubricant attacks viruses that cause STIs such as HIV, genital herpes and human papillomavirus. Laboratory tests have shown the gel can inactivate up to 99.9 percent of those three STIs.

Further, it added that Australia's Therapeutic Goods Administration had approved the use of VivaGel on condoms, paving the way for them to go on sale within months. The company added that the gel will be used on a new line of Ansell condoms sold in Australia.